Study: NCT01958671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg
Description: One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to Ertugliflozin
Description: One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: 500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: 1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: 1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Dosing and titration of glimepiride as rescue therapy was determined by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Dosing and titration of glimepiride as rescue therapy was determined by the investigator.

Intervention type: DRUG
Group type: OTHER
Intervention: Glimepiride
Description: Dosing and titration of glimepiride as rescue therapy was determined by the investigator.